DNA Print vor eklatanter Kurserholung! NEWS! Huge Volume - 500 Beiträge pro Seite

[eichelberg18]

US-Kürzel: DNAG
WKN: A0ETWM


Gestern konnte der Aktienkurs von DNA Print unter noch NIE dagewesenem Volumen über 10 % erwirtschaften.

Das Ausbluten des Aktienkurses dürfte nun endgültig beendet sein da der Makler im Intraday teilweise Kurse oberhalb der 0,023er Marke notierte was einem Kurszuwachs von über 30 % entspricht!



Die gestern vermeldeten News dürften dem Turnaround ebenfalls auf die Sprünge helfen!

http://www.nasdaq.com//aspxcontent/newsstory.aspx?selected=D…

DNA Print war gestern und den TOP 10 der meistgehandeltsten Aktien im OTC-Bereich!

Gestern war sogar endlich wieder Handel in Berlin! 46 K zu 0,021. Falls man in Deutschland ordern will sollte man dies in Berlin tun da offensichtlich dort der Handel liquider ist.

Wir stehen erst ganz am Anfang und habe mir aus diesem Grund nochmals 120 K nachgekauft. Denn hier kann ich von Anfang an dabei sein. Seid Ihr es auch...

[eichelberg18]

gerade mal 1 Verkauforder in Berlin!

Orderbuch Berlin
Verkauf Orders
Limit Stücke
0,022 80.000

[Montha]

[posting]18.125.593 von eichelberg18 am 04.10.05 08:06:03[/posting]wie wärs mit "signifikant" statt eklatant ?

Nur so als Idee

[FCHennes]

Wird Zeit für nen Neuanfang!!!

Mal sehen, hier könnte es bald nach oben gehen.

[Bombenleger]

DNAPrint Genomics Completes Acquisition of Ellipsis Biotherapeutics
Thursday December 22, 7:00 am ET


SARASOTA, Fla., Dec. 22, 2005 -- DNAPrint Genomics, Inc. (OTC BBNAG.OB - News) today announced the completion of its previously announced acquisition of Ellipsis Biotherapeutics Corporation, which will operate as a drug and diagnostic subsidiary.
ADVERTISEMENT


Ellipsis Biotherapeutics, formerly privately held, is retaining its name and will function as a Canadian company from its corporate headquarters in Toronto, Ontario. Ellipsis will retain its existing personnel and continue to be managed by Dr. Laurence Rubin, who is also the Director of the Division of Rheumatology at St. Michael`s Hospital in Toronto. His research has focused on the genetic determinants of osteoporosis, rheumatoid arthritis and other inflammatory diseases. He has been with Ellipsis since 2000.

``The Ellipsis Biotherapeutics acquisition strengthens our position in the diagnostic and clinical patient testing market,`` stated Richard Gabriel, Chief Executive Officer and President of DNAPrint Genomics. ``It also provides potential business opportunities with several large pharmaceutical and animal health care companies currently utilizing Ellipsis`s high throughput screening technologies.``

Ellipsis is located in downtown Toronto in close proximity to the University of Toronto campus, the recently opened MaRS Centre and major academic teaching hospitals. Using the Beckman Coulter GenomeLab SNPstream and the Illumina Beadstation, Ellipsis performs contract SNP genotyping for academic centers, hospitals, human health care corporations and biotech companies in diverse areas covering human, plant and animal analyses. In addition, Ellipsis has acquired a diverse portfolio of genetic data and intellectual property from unique patient populations, specifically with Inflammatory Bowel Disease (Crohn`s disease) including last year`s publications of the discovery of a gene for Crohn`s disease. Diagnostic applications are currently under development in this and related areas of autoimmune inflammatory disorders.

``We are very excited to be part of the DNAPrint group of companies,`` Dr. Laurence Rubin stated. ``Our core competencies provide a unique fit for future growth and development of our contract services as well as opportunities to accelerate novel research programs and collaborations.``

About DNAPrint Genomics, Inc.

DNAPrint Genomics, Inc. (http://www.dnaprint.com) is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company`s proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company`s first theranostic product is PT-401, a ``Super EPO`` (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (end stage renal disease). Pre-clinical and clinical development of all the Company`s drug candidates will benefit from simulated pre-trials to better design actual trials and are targeted to patients with a genetic profile indicating their propensity to have the best clinical response. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to http://www.dnaprint.com for information on law enforcement and consumer applications which include DNAWITNESS(tm), RETINOME(tm), ANCESTRYbyDNA(tm) and EURO-DNA(tm).

Forward-Looking Statements

All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint`s products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint Genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint`s expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.

Contact: DNAPrint Genomics, Inc.
Richard Gabriel, CEO and President
[phone]

The Wall Street Group, Inc.
Ron Stabiner
[phone]




--------------------------------------------------------------------------------
Source: DNAPrint genomics, Inc.

[KohleOle]

Na wer da nicht kauft ist selber Schuld

[KohleOle]

Da tut sich was...

SARASOTA, FL--(MARKET WIRE)--Jan 10, 2006 -- DNAPrint(TM) Genomics, Inc. (OTC BBNAG.OB - News), announced today that it has appointed Barbara Handelin, Ph.D., as Director of Diagnostics, in the newly organized subsidiary, DNAPrint Pharmaceuticals, Inc. As Director, Dr. Handelin will be responsible for the commercialization of the Company`s pharmacogenomics and personalized medicine products. Dr. Handelin is a seasoned biotech business executive and board certified Medical Geneticist (Molecular and Biochemical Genetics) with more than 18 years of experience in the application of genetics to clinical medicine and drug development research.
Dr. Handelin was Director of the DNA Diagnostics Laboratory at Integrated Genetics (now Genzyme Genetics) starting in 1987 where she helped establish what became the largest commercial DNA testing laboratory in the world. Under her direction, the DNA Diagnostics laboratory was a technological and clinical practice leader in genetic diagnostics, setting the standard for low cost, high fidelity analysis of many mutations in genetically complex diseases and the first laboratory to offer commercial carrier and prenatal gene testing for Huntington`s Disease (1987), Cystic Fibrosis (1990), Spinal Muscular Atrophy (1992), Tay Sachs Disease (1993 large scale carrier screening) and Fragile X (1994).

Since 1995, Dr. Handelin has provided business and technical consulting guidance for industry leaders in genetic diagnostics, pharmacogenetics, and drug development. Dr. Handelin has also served on a variety of federal committees and advisory panels on genetic testing and pharmacogenetics, including the Health and Human Services Secretary`s Advisory Panel on Genetics, Health and Society and was the Principal Investigator on a DOE ELSI grant on "The Responsibility of Oversight in Genetics Research: How to Enable Effective Human Subjects Review of Public and Privately Funded Research Programs." Dr. Handelin earned her Ph.D. at the Oregon Health Sciences University and the Massachusetts Institute of Technology.

"Dr. Handelin brings to DNAPrint extensive research and development expertise in the field of Diagnostics, which is crucial to DNAPrint Pharmaceuticals` future growth and development. We are very pleased to be working with her on the development of our diagnostic projects," said Hector J. Gomez, M.D., Ph.D., Chairman and Chief Medical Officer of DNAPrint Genomics, Inc. and the newly formed DNAPrint Pharmaceuticals, Inc.

"DNAPrint Pharmaceuticals is particularly fortunate to have Dr. Handelin lead our diagnostics division. She possesses the technical expertise and business savvy to develop and bring to market products which address significant market opportunities in an efficient and well executed manner," commented Richard Gabriel, President and CEO of DNAPrint.

[KohleOle]

Ende des Monats sollen noch mal News kommen wie es weiter gehen soll. Also ich mag Barbara

[KohleOle]

Jan 18, 2006 (M2 PRESSWIRE via COMTEX) --
www.buyins.net, announced today that these select companies have been added to the NASDAQ, AMEX and NYSE naked short threshold lists: ADA-ES Inc. (NASDAQ: ADES), ASAT Holdings Ltd. (NASDAQ: ASTT), ATA Holdings Corp. (OTC: ATAHQ), China Medical Technologies Inc. (NASDAQ: CMED), DNAprint Genomics, Inc. (OTCBB: DNAG), General Geophysics Co. (NYSE: GGY). For a complete list of companies on the naked short lists please visit our web site. To find the SqueezeTrigger Price before a short squeeze starts in any stock, go to www.buyins.net/squeezetrigger.pdf.

[KohleOle]

DNAPrint Genomics, Inc. Has Licensed a Diabetes Diagnostic Test Developed by Dr. Jose Halperin at Harvard Medical School
Thursday January 26, 7:00 am ET


SARASOTA, FL--(MARKET WIRE)--Jan 26, 2006 -- DNAPrint Genomics, Inc. (OTC BBNAG.OB - News) today announced that the Company and Harvard University have entered into a sponsored research and a field-exclusive licensing agreement. Under the agreement, DNAPrint Genomics, Inc. will sponsor further development in the Laboratory for Translational Research (LTR) at Harvard Medical School of a diagnostic test devised in the Laboratory to target early identification of the population at risk of developing vascular diabetic complications. The Company also will conduct work directed toward its eventual commercialization of the test.
ADVERTISEMENT


Diabetes is the number one cause of renal transplants, blindness and leg amputations. These are all vascular (blood vessel) complications of diabetes and are the most serious and burdensome effects of the disease for diabetic patients. Treatment of these complications of diabetes consumes 10-15% of the overall US health budget. Therefore, early detection of the diabetic population at risk is a major public health priority as set out by the National Heart Lung and Kidney Institute of the National Institutes of Health in the 1990s. Dr. Jose Halperin, head of the LTR, and members of his research group discovered that a molecule -- called CD59 -- which is a regulator of the complement system, appears to be a key player in how small blood vessels are damaged during the spikes in blood glucose levels that are common in diabetic individuals. Continuous damage to these microvessels is the underlying cause of the kidney, nerve and heart disease that more than 60% of diabetic patients suffer over a lifetime. This discovery of a molecule that is a hallmark of such vessel damage will enable DNAPrint Genomics, Inc. to develop a test to identify even very early stages of microvascular complications.

"Unfortunately, by the time patients are diagnosed with a major complication of diabetes, it may be too late for effective therapy by most available medications and changes in life style," said Dr. Hector Gomez, Chairman and Chief Medical Officer of DNAPrint Genomics, Inc. and the newly formed DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary of DNAPrint Genomics, Inc. This collaboration will further the development of new diagnostic tests that will help physicians and healthcare providers re-direct predisposed patients to healthier lifestyle changes and perhaps even some day, medications to help slow down or prevent the onset of vascular diabetic complications.

"This well advanced technology licensed by DNAPrint Genomics Inc. was developed with support from the National Institutes of Health, which funded much of the early discovery work. We are pleased to have the opportunity to sponsor research that will further develop and eventually commercialize this important diagnostic test that could significantly improve the management of diabetes," said Richard Gabriel, CEO and President of DNAPrint Genomics, Inc.

[Quipu]

DNAPrint Genomics Provides Ancestry Test Results for Event Organizers at Human Rights Awareness Conference
SARASOTA, Fla., Feb. 7, 2006 (PRIMEZONE) -- DNAPrint Genomics, Inc. (OTCBBNAG) today announced that it has provided DNA test results to 18 persons of varying ethnic backgrounds who are leaders or organizers of the annual Human Rights Awareness Day, 2006 for the education of approximately 300 high school students in Nassau County, New York.

A workshop at Hofstra University on Thursday, Feb. 9, 2006, entitled "Who Are We Really?" will explore typical stereotypes and perceptions that people may have about each other. The workshop also will help high school juniors understand that genetically they are 99.9% the same as the person sitting next to them, although they may have very different appearances. DNAPrint`s various tests define the anthropological lineages of individuals that can aid students in understanding how they are similar and different from a scientific or genealogical perspective. To demonstrate that ancestry tests often provide surprising results about genetic lineages, 18 conference planners and educators took DNAPrint`s ANCESTRYby DNA(tm) 2.5, and some who qualified took the broadened EURO-DNA 1.0 tests. They plan to share their own test results with attendees of the workshop.

ANCESTRYbyDNA(tm) 2.5 is a pan-chromosomal test for genetic ancestry that reviews 176 Ancestry Informative Markers (AIMs) to provide the percentages of the major bio-geographical population groups, Sub-Saharan African, Indo-European, East Asian or Native American. The AIMs were carefully selected from large-scale screens of the human genome; and are characterized by sequences of DNA that are more prevalent in people from one area of the world than another. EURO-DNA 1.0 breaks Indo-European ancestry into four groups, reporting individuals` percentages for each: Northwestern Europe (Britain, Ireland, Scandinavia, etc.), Southeastern Europe (Italy, Greece, Turkey, etc.), Middle East and South Asia (India and Pakistan).

"The results are sometimes very surprising, but those that have taken the tests are really pleased," said Sgt. Gary Shapiro, Nassau County Police Department and moderator of the panel. "That`s a common response among people who are tested. Some persons who think of themselves as Caucasian thought they would be 100 percent European, and then learn that they have some African, Asian or Native American ancestry. People who describe themselves as Black or African American sometimes discover that the African ancestry is a minority portion of their DNA."

"Avoiding racial stereotypes and learning how closely everyone is related genetically is an important topic for young adults to discuss and understand," stated Richard Gabriel, President and CEO of DNAPrint. "We are pleased to contribute to this valuable event, and we applaud the conference sponsors for undertaking a serious and significant topic that is essential for future generations to understand in order to treat each other with respect. Genealogical and anthropological lessons can also be very interesting and worthwhile from an educational perspective. DNAPrint is proud to participate in valuable public service projects and youth training like the Human Rights Awareness Day. We offer our compliments to Renaire Frieson, the conference chairperson, for putting together this important seminar series for young people."

The Human Rights Awareness Day conference is co-sponsored by the Nassau County Commission on Human Rights and the following organizations; BOCES of Nassau County, Nassau County Police Department, New York Civil Liberties Union, Office of the Nassau County District Attorney, What Color is Love, Inc. and local educators.

[JoJo49]

Hallo Leute,
da ich hier seit längerem investiert bin würden mich insbesondere die Kurssprünge und die gewaltigen Aktienumsätze der vergangenen Woche (ca. 30Millionen) interessieren.

Warauf beruhen diese, was steht dahinter?

Gruß, schönes Wochenende und gute Gedanken.

Name Kurs Veränderung Datum Umsatz
NASDAQ OTC Bulletin Board 0,0244 +4,72% 21:55 17.02. 3.173.326
Xetra n.a. +0,00% 13:24 17.02. n.a.
Berlin-Bremen 0,020 +0,00% 09:16 17.02. n.a.
Frankfurt 0,020 +0,00% 09:05 17.02. n.a.

Performance
Zeitraum Veränderung Zeitraum Datum Kurs
1 Woche +0,00% 52W Hoch 02.01.2006 0,160
1 Monat +0,00% 52W Tief 27.10.2005 0,010
1 Jahr n.a. Jahreshoch 02.01.2006 0,160
laufendes Jahr +25,00% Jahrestief 26.01.2006 0,014

[GlobalKonzept]

Mal was schoenes - Bald gehts rund. Ich glaub die 4 Cent sehen wir schneller als gedacht!

http://quote.barchart.com/texpert.asp?sym=dnag

Ein explosives Wochenende liegt vor uns.

Gruss

GlobalKonzept

[JoJo49]

So ist es!
Positive Ergebnisse führten Gesternabend kurz vor Börsenschluß zu Insiderkäufen. Bei der NASDAQ OTC Bulletin Board 0,0278 +7,34% 21:59 16.03. 5.953.380 Stück gingen über den Ladentisch, bin mal gespannt wie es Heute bei Börseneröffnung um 15:30 abgeht.
Allen Anlegern viel Erfolg ein schönes Wochenende und gute Gedanken

Performance
Zeitraum Veränderung Zeitraum Datum Kurs
1 Woche -20,00% 52W Hoch 14.07.2005 0,15
1 Monat +0,00% 52W Tief 27.10.2005 0,01
1 Jahr n.a. Jahreshoch 14.02.2006 0,038
laufendes Jahr +25,00% Jahrestief 26.01.2006 0,014
Geht es wieder auf 52 Wochen hoch von 0,15€ oder weiter?